Bruker Co. (NASDAQ:BRKR) has received a consensus rating of “Hold” from the eighteen research firms that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, twelve have given a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $31.77.
A number of brokerages recently weighed in on BRKR. JPMorgan Chase & Co. upgraded shares of Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 price objective for the company in a report on Friday, November 3rd. Bank of America upgraded shares of Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 price objective for the company in a report on Friday, November 3rd. Cowen restated a “hold” rating and issued a $29.00 price objective on shares of Bruker in a report on Friday, November 3rd. Citigroup lifted their price objective on shares of Bruker from $29.00 to $34.00 and gave the company a “neutral” rating in a report on Friday, November 3rd. Finally, Zacks Investment Research upgraded shares of Bruker from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a report on Wednesday, November 8th.
Institutional investors have recently modified their holdings of the stock. Zions Bancorporation purchased a new position in Bruker in the third quarter worth approximately $119,000. Bank of Montreal Can lifted its stake in Bruker by 346.7% in the fourth quarter. Bank of Montreal Can now owns 3,708 shares of the medical research company’s stock worth $128,000 after acquiring an additional 2,878 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Bruker by 7.1% in the second quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock worth $144,000 after acquiring an additional 331 shares during the last quarter. SG Americas Securities LLC purchased a new position in Bruker in the fourth quarter worth approximately $145,000. Finally, Advisory Services Network LLC lifted its stake in Bruker by 6.3% in the second quarter. Advisory Services Network LLC now owns 6,847 shares of the medical research company’s stock worth $197,000 after acquiring an additional 406 shares during the last quarter. Institutional investors own 64.78% of the company’s stock.
Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, February 8th. The medical research company reported $0.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.02. Bruker had a net margin of 4.45% and a return on equity of 26.58%. The business had revenue of $530.50 million during the quarter, compared to analysts’ expectations of $506.74 million. During the same period last year, the business earned $0.46 earnings per share. The business’s revenue for the quarter was up 12.8% on a year-over-year basis. equities analysts forecast that Bruker will post 1.36 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Bruker Co. (BRKR) Given Average Rating of “Hold” by Brokerages” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/13/bruker-co-brkr-given-average-rating-of-hold-by-brokerages.html.
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.